Oramed Pharmaceuticals/ORMP

$2.32

-0.85%
-
1D1W1MYTD1YMAX

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Ticker

ORMP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nadav Kidron

Employees

15

Headquarters

New york, United States
Website
oramed.com

ORMP Metrics

BasicAdvanced
$95M
Market cap
9.41
P/E ratio
$0.25
EPS
1.81
Beta
-
Dividend rate
$95M
1.80658
$4.36
$1.67
120K
5.278
19.224
-4.851
5.63%
6.58%
6.27%
9.407
141.056
0.569
0.571
-75.06%
133.01%

What the Analysts think about ORMP

Analyst Ratings

Majority rating from 2 analysts.
Hold

Price Targets

Average projection from 1 analyst.
83.19% upside
High $4.25
Low $4.25
$2.32
Current price
$4.25
Average price target

ORMP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
$1.5M
-88.72%
Profit margin
0%
NaN%

ORMP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 100%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.08
$0.33
$0.04
-
Expected
-$0.10
-$0.09
-$0.12
$0.02
-$0.02
Surprise
-70%
-5.88%
-375%
100%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals (ORMP) has a market cap of $95M as of May 28, 2024.

What is the P/E ratio for Oramed Pharmaceuticals stock?

The price to earnings (P/E) ratio for Oramed Pharmaceuticals (ORMP) stock is 9.41 as of May 28, 2024.

Does Oramed Pharmaceuticals stock pay dividends?

No, Oramed Pharmaceuticals (ORMP) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Oramed Pharmaceuticals dividend payment date?

Oramed Pharmaceuticals (ORMP) stock does not pay dividends to its shareholders.

What is the beta indicator for Oramed Pharmaceuticals?

Oramed Pharmaceuticals (ORMP) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Oramed Pharmaceuticals stock price target?

The target price for Oramed Pharmaceuticals (ORMP) stock is $4.25, which is 83.19% above the current price of $2.32. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Oramed Pharmaceuticals stock

Buy or sell Oramed Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing